There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avanos Medical (AVNS – Research Report), Karuna Therapeutics (KRTX – Research Report) and Beam Therapeutics (BEAM – Research Report) with bullish sentiments.
Avanos Medical (AVNS)
In a report released today, Matthew Mishan from KeyBanc maintained a Buy rating on Avanos Medical, with a price target of $38.00. The company’s shares closed last Tuesday at $28.84.
According to TipRanks.com, Mishan is a 4-star analyst with an average return of
Currently, the analyst consensus on Avanos Medical is a Hold with an average price target of $31.33.
See the top stocks recommended by analysts >>
Karuna Therapeutics (KRTX)
In a report released today, Jacob Hughes from Wells Fargo maintained a Buy rating on Karuna Therapeutics, with a price target of $264.00. The company’s shares closed last Tuesday at $228.45.
Hughes has an average return of
According to TipRanks.com, Hughes is ranked #4239 out of 7991 analysts.
Currently, the analyst consensus on Karuna Therapeutics is a Strong Buy with an average price target of $241.07, implying a -1.9% downside from current levels. In a report issued on August 8, Citigroup also maintained a Buy rating on the stock with a $280.00 price target.
Beam Therapeutics (BEAM)
In a report released today, Rick Bienkowski from SVB Securities maintained a Buy rating on Beam Therapeutics, with a price target of $113.00. The company’s shares closed last Tuesday at $60.96.
According to TipRanks.com, Bienkowski is ranked #5529 out of 7991 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Beam Therapeutics with a $90.25 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVNS:
- These Stocks Are the Biggest Pre-Market Movers on Wednesday
- Certara (CERT) Receives a Buy from SVB Securities
- RBC Capital Reaffirms Their Buy Rating on Caribou Biosciences (CRBU)
- RBC Capital Keeps Their Buy Rating on Allogene Therapeutics (ALLO)
- Raymond James Reaffirms Their Buy Rating on Gossamer Bio (GOSS)